Skip to main content
Log in

The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Single-dose investigations in healthy subjects have demonstrated substantial impairment of renal and extrarenal clearance of digoxin during coadministration of verapamil. A longitudinal study has been performed to assess the changes in digoxin disposition during long-term verapamil therapy. After one week of verapamil 240 mg/d mean plasma digoxin had risen from 0.21±0.01 ng/ml (SE) to 0.34±0.01 ng/ml (p<0.01), and renal digoxin clearance had fallen from 197.57±17.37 ml/min to 128.20±10.33 ml/min (p<0.001). These changes gradually subsided, and after six weeks, renal digoxin clearance had normalized and plasma digoxin had declined to 0.27±0.02 ng/ml (NS). The 24-h urinary recovery of digoxin increased from 46.46±3.23% before to 69.78±3.69% (p<0.001) after six weeks of verapamil co-administration, and this elevation persisted throughout the study. The verapamil-induced suppression of renal digoxin elimination disappears over a few weeks of drug exposure, whereas the inhibition of the extrarenal clearance of digoxin seems to persist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hager WD, Fenster P, Mayersohn M, Perrier D, Graves P, Marcus FI, Goldman S (1979) Digoxin-Quindine interaction. Pharmacokinetic evaluation. N Engl J Med 300: 1238–1241

    Google Scholar 

  2. Pedersen KE, Hastrup J, Hvidt S (1980) The effect of quinidine on digoxin kinetics in cardiac patients. Acta Med Scand 207: 291–296

    Google Scholar 

  3. Waldorff S, Andersen JD, Heebøll N, Nielsen OG, Moltke E, Sørensen U, Steiness E (1978) Spironolactoneinduced changes in digoxin kinetics. Clin Pharmacol Ther 24: 162–167

    Google Scholar 

  4. Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Nielsen-Kudsk F (1981) Digoxin-verapamil interaction, a singledose pharmacokinetic study. Clin Pharmacol Ther 30: 311–317

    Google Scholar 

  5. Ochs HR, Bodem G, Bales G, Greenblatt DJ, Smith TW (1978) Increased clearance of digoxin in rabbits during repeated administration. Clin Pharmacol Ther 204: 262–270

    Google Scholar 

  6. Ford AR, Aronson JK, Grahame-Smith DG, Carver JG (1979) The acute changes seen in cardiac glycoside receptor sites, 86Rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: Pharmacological and therapeutic implications for chronic digoxin therapy. Br J Clin Pharmacol 8: 135–142

    Google Scholar 

  7. Belz GG, Aust PE, Munkes R (1981) Digoxin plasma concentrations and nifedipine. Lancet 1: 844–845

    Google Scholar 

  8. Klein HO, Lang K, Segni ED, Kaplinsky E (1980) Verapamil-digoxin interaction. N Engl J Med 303: 160

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pedersen, K.E., Dorph-Pedersen, A., Hvidt, S. et al. The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects. Eur J Clin Pharmacol 22, 123–127 (1982). https://doi.org/10.1007/BF00542456

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00542456

Key words

Navigation